Hat mitgewirkt an:
-
Responseabschätzung der (177Lu)PSMA-617-Radioligandentherapie bei Patienten mit fortgeschrittenem, metastasiertem Prostatakarzinom
-
Bone marrow impairment during early [177Lu]PSMA-617 radioligand therapy: Haematotoxicity or tumour progression?
-
Early PSA change after [177Lu]PSMA-617 radioligand therapy as a predicator of biochemical response and overall survival
-
Combining PSMA-PET and PROMISE to re-define disease stage and risk in patients with prostate cancer: a multicentre retrospective study